These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17331716)

  • 21. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction.
    Zeller M; Masson D; Farnier M; Lorgis L; Deckert V; Pais de Barros JP; Desrumaux C; Sicard P; Grober J; Blache D; Gambert P; Rochette L; Cottin Y; Lagrost L
    J Am Coll Cardiol; 2007 Nov; 50(20):1948-55. PubMed ID: 17996559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists.
    Chen JJ; Qian W; Biswas K; Viswanadhan VN; Askew BC; Hitchcock S; Hungate RW; Arik L; Johnson E
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4477-81. PubMed ID: 18674903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-Arylbenzoxazoles as novel cholesteryl ester transfer protein inhibitors: optimization via array synthesis.
    Harikrishnan LS; Kamau MG; Herpin TF; Morton GC; Liu Y; Cooper CB; Salvati ME; Qiao JX; Wang TC; Adam LP; Taylor DS; Chen AY; Yin X; Seethala R; Peterson TL; Nirschl DS; Miller AV; Weigelt CA; Appiah KK; O'Connell JC; Michael Lawrence R
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2640-4. PubMed ID: 18374566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromanol derivatives--a novel class of CETP inhibitors.
    Vakalopoulos A; Schmeck C; Thutewohl M; Li V; Bischoff H; Lustig K; Weber O; Paulsen H; Elias H
    Bioorg Med Chem Lett; 2011 Jan; 21(1):488-91. PubMed ID: 21084191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. General asymmetric hydrogenation of 2-alkyl- and 2-aryl-substituted quinoxaline derivatives catalyzed by iridium-difluorphos: unusual halide effect and synthetic application.
    Cartigny D; Berhal F; Nagano T; Phansavath P; Ayad T; Genêt JP; Ohshima T; Mashima K; Ratovelomanana-Vidal V
    J Org Chem; 2012 May; 77(10):4544-56. PubMed ID: 22519599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport.
    Tanigawa H; Billheimer JT; Tohyama J; Zhang Y; Rothblat G; Rader DJ
    Circulation; 2007 Sep; 116(11):1267-73. PubMed ID: 17709636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules.
    Qiu X; Mistry A; Ammirati MJ; Chrunyk BA; Clark RW; Cong Y; Culp JS; Danley DE; Freeman TB; Geoghegan KF; Griffor MC; Hawrylik SJ; Hayward CM; Hensley P; Hoth LR; Karam GA; Lira ME; Lloyd DB; McGrath KM; Stutzman-Engwall KJ; Subashi AK; Subashi TA; Thompson JF; Wang IK; Zhao H; Seddon AP
    Nat Struct Mol Biol; 2007 Feb; 14(2):106-13. PubMed ID: 17237796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy.
    Sweis RF; Hunt JA; Kallashi F; Hammond ML; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Wright SD; Anderson MS; Sinclair PJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1890-5. PubMed ID: 21147531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conformationally restricted analog and biotin-labeled probe based on beauveriolide III.
    Doi T; Muraoka T; Ohshiro T; Matsuda D; Yoshida M; Takahashi T; Omura S; Tomoda H
    Bioorg Med Chem Lett; 2012 Jan; 22(1):696-9. PubMed ID: 22079027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins.
    Dallinga-Thie GM; Dullaart RP; van Tol A
    Curr Opin Lipidol; 2007 Jun; 18(3):251-7. PubMed ID: 17495597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
    Trieselmann T; Wagner H; Fuchs K; Hamprecht D; Berta D; Cremonesi P; Streicher R; Luippold G; Volz A; Markert M; Nar H
    J Med Chem; 2014 Nov; 57(21):8766-76. PubMed ID: 25265559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.
    Kuo GH; Rano T; Pelton P; Demarest KT; Gibbs AC; Murray WV; Damiano BP; Connelly MA
    J Med Chem; 2009 Mar; 52(6):1768-72. PubMed ID: 19236017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
    Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
    Abu Khalaf R; Abu Sheikha G; Bustanji Y; Taha MO
    Eur J Med Chem; 2010 Apr; 45(4):1598-617. PubMed ID: 20116902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
    Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
    Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.
    Seiler S; Schlitt A; Jiang XC; Ulrich C; Blankenberg S; Lackner KJ; Girndt M; Werdan K; Buerke M; Fliser D; Heine GH
    Nephrol Dial Transplant; 2008 Nov; 23(11):3599-604. PubMed ID: 18503096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology.
    Eveland SS; Milot DP; Guo Q; Chen Y; Hyland SA; Peterson LB; Jezequel-Sur S; O'Donnell GT; Zuck PD; Ferrer M; Strulovici B; Wagner JA; Tanaka WK; Hilliard DA; Laterza O; Wright SD; Sparrow CP; Anderson MS
    Anal Biochem; 2007 Sep; 368(2):239-49. PubMed ID: 17601482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
    Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.